
With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.
Voxelotor (Oxbryta) is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older.
Medication Pearl of the Day: Voxelotor (Oxbryta)
Indication: Voxelotor (Oxbryta) is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older.
Insight:
Reference






